Department of Health Services, University of Washington , Seattle, WA.
Pharmaceutical Outcomes Research and Policy Program, University of Washington , Seattle, WA.
Appl Clin Inform. 2013 Oct 16;4(4):476-98. doi: 10.4338/ACI-2013-06-RA-0041. eCollection 2013.
Stage 2 Meaningful Use criteria require the use of clinical decision support systems (CDSS) on high priority health conditions to improve clinical quality measures. Although CDSS hold great promise, implementation has been fraught with challenges, evidence of their impact is mixed, and the optimal method of content delivery is unknown.
The authors investigated whether implementation of a simple clinical decision support (CDS) tool was associated with improved prescriber adherence to national medication-laboratory monitoring guidelines for safety (hepatic function, renal function, myalgias/rhabdomyolysis) and intermediate outcomes for antidiabetic (Hemoglobin A(1c); HbA(1c)) and antihyperlipidemic (low density lipoprotein; LDL) medications prescribed within a diabetes registry.
This was a retrospective observational study conducted in three phases of CDS implementation (2008-2009): pre-, transition-, and post-Prescriptions evaluated were ordered from an electronic health record within a multispecialty medical group. Adherence was evaluated within and without applying guideline-imposed time constraints.
Forty-thousand prescriptions were ordered over three timeframes. For hepatic and renal function, the proportion of prescriptions for which labs were monitored at any time increased from 52% to 65% (p<0.001); those that met time guidelines, from 14% to 21% (p<0.001). Only 6% of required labs were drawn to monitor for myalgias/rhabdomyolysis, regardless of timeframe. Over 90% of safety labs were within normal limits. The proportion of labs monitored at any time for LDL increased from 56% to 64% (p<0.001); those that met time guidelines from 11% to 17% (p<0.001). The proportion of labs monitored at any time for HbA(1c) remained the same (72%); those that met time guidelines decreased from 45% to 41% (p<0.001).
A simple CDS tool may be associated with improved adherence to guidelines. Efforts are needed to confirm findings and improve the timeliness of monitoring; investigations to optimize alerts should be ongoing.
第二阶段有意义的使用标准要求在高优先级健康状况下使用临床决策支持系统(CDSS),以提高临床质量指标。尽管 CDSS 具有很大的潜力,但实施过程中充满了挑战,其影响的证据参差不齐,并且不知道最佳的内容传递方法。
作者研究了实施简单的临床决策支持(CDS)工具是否与改善开处方者对国家药物-实验室监测指南的遵守情况有关,这些指南针对的是糖尿病登记处中规定的安全性(肝功能、肾功能、肌痛/横纹肌溶解症)和抗糖尿病(糖化血红蛋白;HbA(1c))和抗高脂血症(低密度脂蛋白;LDL)药物的处方的中间结果。
这是一项回顾性观察性研究,在 CDS 实施的三个阶段(2008-2009 年)进行:预、过渡和后-从一个多专业医疗集团的电子健康记录中评估了所开的处方。在不应用指南规定的时间限制的情况下,评估了依从性。
在三个时间框架内,共开出了 4 万张处方。对于肝功能和肾功能,任何时候都监测实验室的处方比例从 52%增加到 65%(p<0.001);符合时间指南的比例从 14%增加到 21%(p<0.001)。无论在哪个时间段,都只有 6%的所需实验室被抽取来监测肌痛/横纹肌溶解症。超过 90%的安全实验室都在正常范围内。任何时候监测 LDL 的实验室比例从 56%增加到 64%(p<0.001);符合时间指南的比例从 11%增加到 17%(p<0.001)。任何时候监测 HbA(1c)的实验室比例保持不变(72%);符合时间指南的比例从 45%下降到 41%(p<0.001)。
简单的 CDS 工具可能与改善对指南的遵守有关。需要努力确认研究结果并提高监测的及时性;正在进行以优化警报的调查。